Clinical Trial Update: Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating safety and efficacy of different PANZYGA dose regimens in pediatric chronic inflammatory demyelinating polyneuropathy; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Panzyga (intravenous immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Status: RECRUITING